Skip Navigation
Skip to contents

Perspect Integr Med : Perspectives on Integrative Medicine

OPEN ACCESS
SEARCH
Search

Articles

Page Path
HOME > Perspect Integr Med > Volume 5(2); 2026 > Article
Protocol
Efficacy of Bhringaraja Arka as an Add–On to Standard Care in the Management of Neonatal Jaundice – A Study Protocol for an Open Labelled Randomized Controlled Clinical Trial
Sreesha M S*orcid, Bhinde Sagar Morcid
Perspectives on Integrative Medicine 2026;5(2):147-151.
DOI: https://doi.org/10.56986/pim.2026.06.008
Published online: June 19, 2026

Department of Kaumarbhritya, Institute of Teaching and Research in Ayurveda, Jamnagar, India

*Corresponding author: Sreesha M S, Department of Kaumarbhritya, Room No. 533, 5th floor, ITRA building, Gujarat Ayurveda University Campus, Jamnagar, Gujarat 361008, India, Email: sreeshasanthosh798@gmail.com
• Received: August 13, 2025   • Revised: March 13, 2026   • Accepted: April 29, 2026

©2026 Jaseng Medical Foundation

This is an open access article under the CC BY-NC license (http://creativecommons.org/licenses/by-nc/4.0/).

prev next
  • 1,554 Views
  • 34 Download
  • Background
    Neonatal jaundice (NNJ) is common biochemical hyperbilirubinemia, affecting 85% of term and 95% of preterm infants in India. Mild cases are self-limiting, but severe NNJ (Serum Bilirubin > 15 mg/dL) remains a global concern, especially in low- and middle-income countries. Severe hyperbilirubinemia can cause long-term neurocognitive sequelae such as cerebral palsy, auditory neuropathy, deafness, and increased mortality. Current treatments include phototherapy, exchange transfusion, and phenobarbitone, although each has limitations. Phototherapy may lead to loose stools, dehydration, rashes, and retinal damage, whilst phenobarbitone can cause somnolence and dependence. Bhringaraja (Eclipta prostrata L.), traditionally used in Ayurveda for liver disorders and hyperbilirubinemia, has been investigated as a complementary therapy. It acts as a Rakta Shodhaka (blood purifier) and Pittahar (Pitta-balancer). Phytochemicals like wedelolactone and ecliptine provide hepatoprotective effects including, supporting hepatocyte function, metabolism, and bilirubin clearance. Despite its long traditional use in NNJ, scientific evaluation of efficacy is lacking.
  • Methods
    Eligible NNJ patients will be randomized into two groups (≥ 20 each). Group A will receive Bhringaraja Arka (5 drops 3×daily) plus standard care, while Group B will receive standard care alone (clinical observation and phototherapy if required). Treatment will continue for 7 days or until Serum Bilirubin reaches remission levels.
  • Conclusion
    This study protocol aims to produce a study which will generate evidence on the potential of Bhringaraja Arka to determine whether it accelerates recovery and prevent NNJ progression.
  • Trial registration
    Clinical Trials Registry - India (CTRI) (CTRI/2025/04/084172; date of registration : 4 April 2025).
Neonatal jaundice (NNJ), defined as the yellow pigmentation of the sclera, skin, and urine due to hyperbilirubinemia, is a pervasive clinical challenge, affects approximately 85% of term infants and the majority of preterm infants in India [1]. Its etiology stems from increased bilirubin production, reduced hepatic clearance, and enhanced enterohepatic circulation. Whilst many cases are physiological, pathological hyperbilirubinemia, especially when severe, is a serious global health concern due to the risk of kernicterus, which can result in long-term neurocognitive sequelae, including cerebral palsy, and deafness. Therefore, early detection and management of hyperbilirubinemia are paramount [2].
Current treatments of hyperbilirubinemia, including phototherapy, exchange blood transfusion, and phenobarbitone, effectively reduce serum bilirubin (SB) but are associated with significant drawbacks [3]. Phototherapy, for example, can cause immediate side effects such as dehydration, skin rashes, and late side effects like potential retinal damage, skin cancer, and photoaging. Similarly, phenobarbitone administration can lead to excessive somnolence and in long term use there is risk of dependence. These limitations necessitate the exploration of safer, adjunctive therapies to effectively combat the progression of NNJ [4].
The clinical presentation of NNJ closely parallels the condition of Kamala described in classical Ayurvedic texts. Kamala is characterized as a Pittaja Nanatmaja Vyadhi and a Rakta Pradoshaja Vikara [5]. Specifically, the infant condition is often attributed to Pittaja Dushta Sthanya (vitiated breast milk), resulting in jaundice, and systemic heat in the newborn [6]. This Ayurvedic etiology directly aligns with the contemporary understanding of NNJ pathophysiology, where increased Pitta (a hot entity) and Rakta vitiation correspond to the systemic accumulation and toxicity of bilirubin.
Bhringaraja (Eclipta prostrata L. Syn: Eclipta alba Hassk) was selected as the therapeutic agent. This herb is used in Ayurvedic medicine for liver disorders (Yakritvikaras) and jaundice (Kamala). The central hypothesis is that Bhringaraja acts by virtue of its hepatotonic and Pitta balancing properties. This is supported by its phytochemical content (e.g., wedelolactone and ecliptine), used to protect hepatocytes, thereby improving immature liver function and enhancing the conjugation and clearance of bilirubin, which is the key deficit in NNJ [7]. The traditional use of Bhringaraja is supported by preclinical evidence, showing that its extracts significantly reduced elevated aspartate aminotransferase, alanine aminotransferase, and bilirubin levels in models of liver toxicity. Despite strong traditional and preclinical justification, the efficacy and safety of Bhringaraja Arka as an adjunctive therapy for NNJ have not been rigorously evaluated through a controlled clinical study. This study protocol for a clinical trial will address this need with the medication, which will be prepared as Bhringaraja Arka. This distilled essence was chosen because infants (Ksheerada) possess Mandagni (weak digestive fire) [8]. Arka represents the most bioavailable preparation (Kashaya Kalpana), while the distillation process ensures sterilization and palatability, which is critical for neonatal administration [9].
1. Study design and study setting
The study is designed as an open-label, randomized controlled clinical trial to be conducted in the Outpatient and Inpatient Department at the Institute of Teaching and Research in Ayurveda, Jamnagar, Gujarat, India. The study aims to enroll a total of 40 patients, that fulfill the selection criteria, over a period of 1 year and 6 months.
2. Sample size
To calculate the sample size for the study, a confidence interval 95% was taken with a 15% margin of error. By assuming the population as 50% the sample size was calculated.
n=(Z^2×p×(1-p))/E^2
Where:
  • ● n = required sample size

  • ● Z = Z-score (e.g., 1.96 for 95% confidence level)

  • ● p = estimated proportion of the population with the characteristic of interest

  • ● E = margin of error (desired precision level)

By substantiating values into this formula, a calculated sample size is determined as 43. Considering a 10% drop out in the study, the calculated sample size is 46, that is 23 in each group. However, limited by time constraints and budget the target sample size was kept 40.
3. Pragmatic sample size adjustment and power analysis
Due to constraints related to the study timeline and budget, the final sample size was pragmatically set at a total of 40 patients (20 patients per group). Based on this reduction, a post-hoc power analysis was performed. Assuming an expected mean difference in the primary outcome (days to recovery) of 2 days and a standard deviation of 3 days, the study is calculated to have a statistical power of approximately 54% to detect this difference at an alpha level of 0.05. This reduced sample size is a significant limitation, and the study is underpowered to detect smaller, clinically relevant differences between the two groups.
4. Study participants

4.1. Diagnostic assessment

Newborns have a bilirubin level ≥ 5mg/dL, as per Kramer’s criteria or be diagnosed as NNJ using a transcutaneous bilirubin (TcB) meter.

4.2. Inclusion criteria

The study will include both term and late preterm infants weighing more than 2,500 g and diagnosed with NNJ, regardless of sex, caste, or creed.

4.3. Exclusion criteria

Newborns with birth asphyxia or an Apgar score < 7 after 5 minutes, or newborns with congenital anomalies or medical or surgical illness will be excluded from the study.

4.4. Investigation

The laboratory parameters will include a complete blood count and total, direct, indirect bilirubin (before and after treatment). A TcB reading will be taken daily with a transcutaneous bilirubinometer
5. Study interventions

5.1. Posology of drug

As per the Sharangadhara Samhita dose fixation guideline, the dose of medicine (in Kalka form) for a baby up to 1 month of age is 1 and for Kashaya (decoction - based formulation) it is 4× the dose i.e. 4 Ratti [10]. Four Ratti is equal to 500mg (approximately equal to 0.5 mL i.e., 14–15 drops Bhringaraja Arka. Hence the dose is fixed as 5 drops 3× per day (before feeding).
Bhringaraja Arka will be provided for 7 days or until the remission of jaundice. Post-treatment follow-up will be taken on 7th day after the treatment. The total duration of the study will be approximately 14 days.

5.2. Grouping

All patients will be assigned to groups by computer generated randomization, and there will be a minimum of 20 patients per group (Table 1). Group A (Trial group): Newborns will be administered 5 drops of Bhringaraja Arka orally 3× per day for 7 days or until the remission of jaundice. Phototherapy, as and when indicated, will be provided as a part of Standard Care. Group B (Standard control): Newborn will be kept under observation, and phototherapy as and when indicated will be provided as a part of Standard Care.

5.3. Observation

According to the standard protocols of the Indian Academy of Pediatrics and the new American Academy of Pediatrics guidelines 2022, the need for visual assessments of jaundice every 12 hours after birth and need to measure either TcB or SB (if jaundice presents in the first 24 hours of life) is emphasized. It is now recommended that bilirubin (TcB or SB) is measured in all babies between 24 to 48 hours of life as visual inspection is deemed far too inaccurate to assess the level of jaundice.
SB should be used as the definitive test, to guide the need for phototherapy or exchange transfusion, TcB values are valid screen to determine the need for SB estimation and they decrease the need for sampling [11].

5.4. Indication of phototherapy

The indication for initiating phototherapy in newborns is based on the newborn age in hours and the SB levels. For neonates less than 24 hours old, phototherapy is generally not indicated. For those aged between 25 to 48 hours, phototherapy should be considered if the bilirubin level is ≥ 12 mg/dL, and it should be started if the level reaches 15 mg/dL. Exchange transfusion is recommended if the bilirubin level is ≥ 20 mg/dL. In infants aged 49 to 72 hours, phototherapy is considered at 15 mg/dL, and started at 18 mg/dL, while exchange transfusion is indicated at ≥ 25 mg/dL. For neonates older than 72 hours, phototherapy is considered at 17 mg/dL and started at 20 mg/dL, with exchange transfusion recommended if the bilirubin level is ≥ 25 mg/dL [12].
6. Outcome measures (with timeline)

6.1. Primary

Primary outcomes include the number of days/hours required for recovery from NNJ (after treatment) and the number of neonates who required phototherapy (after treatment).

6.2. Secondary

Secondary outcomes include the number of days required for phototherapy (after treatment); and the SB level hematological measured (before and after treatment).

6.3. Safety outcomes

Safety outcomes will be evaluated by monitoring adverse events daily. Any observed adverse will be documented following Good Clinical Practice guidelines.

6.4. Withdrawal criteria

The parent or carer will be allowed to withdraw the participant from the trial if there is any major ailment necessitating the institution of new modalities of treatment. Those neonates whose total SB level reached 20 mg/dL during the course of treatment will be withdrawn from the study and will be referred to the higher centers.

6.5. Ethical consideration

The protocol for this study was approved by the Institutional Ethics Committee of Institute of Teaching and Research in Ayurveda, Jamnagar, Gujarat, India. This proposed study is prospectively registered at Clinical Trials Registry - India (CTRI) (reference no.: CTRI/2025/04/084172 on the date 04/04/2025). Written informed consent will be obtained from the care giver of the patients, by the investigator, before enrolling. The Indian Council of Medical Research National Ethical Guidelines for Biomedical and Health Research on Human Participants (2017) will be followed to execute the study.

6.6. Concomitant and rescue medication

Any concurrent medication being taken for unrelated health issues will be recorded in the case report form (CRF). In instances where rescue medication is deemed necessary, it will be prescribed and noted in the CRF.

6.7. Compliance

The evaluation of compliance will be based on the amount of trial medication consumed throughout the intervention period. Participants must exhibit a compliance rate ≥80%.

6.8. Data collection and documentation

Data on the participants will be collected at baseline and throughout the intervention. The assessment will be at baseline, based on the 1st and 2nd follow-up, and tabulated in the CRF. The data of discontinued patients will also be collected based on their willingness.

6.9. Deviation from protocol

In the event of any protocol deviation during the study, the investigator will document the deviation in detail, and assess its impact on participant safety and study outcomes. Appropriate corrective actions will be implemented, and necessary adjustments to the study protocol will be submitted for approval from the ethics committee if required. All protocol deviations will be systematically documented and the Institutional Ethics Committee will be informed.

6.10. Confidentiality

Unique identification numbers will be assigned to each participant to ensure the confidentiality of participant information. Access to confidential data will be limited to authorized research personnel, and all data will be securely stored.

6.11. Monitoring

The study will be monitored by the supervisor of the department where the study will be conducted (Outpatient and Inpatient Department).All neonates will be closely monitored under the supervision of a senior neonatologist. SB levels will be checked at predefined intervals, and predefined bilirubin escalation thresholds will be used to guide treatment decisions. If bilirubin levels crossed the recommended clinical thresholds, appropriate escalation of treatment will be undertaken according to institutional guidelines for neonatal care.

6.12. Statistical analysis

The data will undergo comprehensive analysis utilizing statistical tests. The unpaired t-test will be used to evaluate the mean days required in phototherapy. Risk ratio will be applied to determine the number of participants who require phototherapy. The repeated measure Analysis of Variance will be applied to determine the mean difference of TcB. A Time to Event Kaplan-Meier curve will be applied to evaluate the recovery time from NNJ. Statistical calculations will be performed with the help of SigmaStat Version 3.5 software or SPSS software. The results will be interpreted as significant if p < 0.05.
In this protocol, the values obtained from TcB study will be utilized for day-to-day evaluation to monitor the trend of SB levels in both groups. The use of TcB is supported by the American Academy of Pediatrics as a noninvasive tool to screen and diagnosis hyperbilirubinemia. The TcB is a universal screening tool used during and after phototherapy, and it minimizes the need for repeated, invasive blood sampling in neonate
The treatment protocol for the study involves providing Standard Care along with Bhringaraja Arka for a maximum of 7 days or until the SB level reaches normal limits. This adjustable timeline will be crucial to ensure the primary endpoint (cure of NNJ). This acknowledges the possibility of encountering cases of pathological jaundice (which may require a longer intervention time compared with typical physiological cases of jaundice).
A robust plan for home care and data collection will minimize dropout rates and ensure data completeness. In cases where the mother and child are discharged from the Inpatient Department (IPD), parents will be educated on the regular administration of the interventional drug. TcB values will then be collected by the researcher during scheduled home visits (twice daily), which will be a key strength for maintaining consistency and compliance.
Folklore and traditional use of Eclipta prostrata (E. alba) for conditions like jaundice and other liver pathologies are widely documented. This traditional use is supported by strong preclinical evidence [13]. Specifically, the aqueous extracts of E. alba, when orally administered in CCl4-induced liver-injured rats, significantly prevented the increase of alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, and SB [14]. Similar hepatoprotective effects have been demonstrated against paracetamol-induced hepatocellular damage in mice, providing scientific validation for its application in liver-related diseases.
Whilst the plant can be administered in the forms of Swarasa (juice), due to the age of the patient population (neonates), the form will be converted to Arka (water distillation). This conversion to Arka thermally sterilizes the formulation, avoids sugar additives, and is more palatable which, significantly eases the process of drug administration for the baby and caretaker.
Though NNJ is often self-limiting, the protocol sets out a study to determine whether an Ayurvedic intervention add on can provide early remission, and critically, prevent the chances of a controllable condition becoming severe. Hence, preventing progression of NNJ severity is a major clinical outcome of this study. Preventing severe jaundice, in turn, prevents the development of kernicterus and bilirubin-induced brain damage, thereby preventing serious neurological complications like cerebral palsy in children, which highlights the profound clinical relevance of this research. Despite these strengths, this protocol has inherent methodological limitations in the intended study which warrant consideration Firstly, the study will utilize an open-label design. This is pragmatic for a single-center trial involving a known herbal intervention, however, it introduces the potential for detection bias amongst the researchers and caregivers as they are aware of the treatment assignment. Secondly, the sample size was pragmatically reduced due to time and budget constraints (N = 46 versus intended sample size N = 40). This reduced sample size may render the potential study too small to detect a true effect or show a statistically significant differences between the Bhringaraja Arka group and the control group. Therefore, results from the intended study, particularly nonsignificant findings, must be interpreted cautiously, and should serve as preliminary data for a subsequent, larger, sufficiently powered clinical trial.

Author Contributions

Collection of data, analyzed the results, drafted the manuscript: SS. Conceptualization, Supervision, review, and editing: BM. All authors reviewed and approved the final manuscript.

Conflicts of Interest

The authors have no conflicts of interest to declare.

Author Use of AI Tools Statement

The authors used AI Tools for language editing and manuscript preparation support. No AI tool was involved in data interpretation or final decision-making.

Funding

None.

Ethics Statement

This study is prospectively registered at CTRI (reference no.: CTRI/2025/04/084172 on the date 04/04/2025).

The investigator and coinvestigator would have full access to the treatment dataset for data validation.
pim-2026-06-008f1.jpg
Table 1
Intervention and Treatment Protocol for Both Groups in Neonatal Jaundice
No. Intervention Duration
Group A Group B
1 Bhringaraja Arka Nil 7 d or until remission
2 Standard care
Observation
Phototherapy if needed
Standard care
A. Observation
B. Phototherapy if needed
7 d or until remission
3 Post treatment
Follow up
Post treatment
Follow up
7 d after the treatment

N.B. (Total duration of study will be 14 days).

  • [1] Rathore S, Kumar Vk C, Sharashchandra R. A critical review on neonatal hyperbilirubinemia-an Ayurvedic perspective. J Ayurveda Integr Med 2020;11(2):190−6.ArticlePubMedPMC
  • [2] Eichenwald EC, Hansen AR, Martin CR, Stark AR. Cloherty and Stark’s manual of neonatal care. 8th ed. Philadelphia (PA), Wolters Kluwer, 2017, p 335.
  • [3] McInerny TK, Adam HM, Campbell DE, DeWitt TG, Foy JM, Kamat DM, et al. American academy of pediatrics textbook of pediatric care. Washington DC (WA), American Academy of Pediatrics, 2009.
  • [4] Gupta P, Menon PSN, Ramji S, Lodha R, editor. PG textbook of pediatrics. 1st ed. New Delhi (India): Jaypee Brothers Medical Publishers; 2015. 438.
  • [5] Jeevaka V. [Internet]. Kashyapa samhita: Varanasi (India); e-samhita: 2010 Verse 43-73. 193−9. Available from: https://esamhita.wordpress.com/kashyapa-samhita/ [in Indian].
  • [6] Agnivesha , Samhita Charaka, Kushwaha HS, editor. Hindi Commentry by Chakrapanidatta on Charaka Samhita of Agnivesha. 1st ed. 4:Chikitsa Sthana. Varanasi India: Chaukhambha Orientalia; 2009. Chapter 16, verse 428-34, 433-4, 439-40, 435-7, 430-2, 441-2. Available from: https://niimh.nic.in/ebooks/ecaraka/?mod=read.
  • [7] Sidh V, Sharma O. Medicinal use of Bhringraja (Eclipta alba hassk.): a review article. World J Pharm Med Rese 2019;5(7):39−40.
  • [8] Samhita Sushruta Murthy KR . Illustrated Susruta Samhita: Text, English Translation, Notes, Appendices and Index. Vol 1 Sutrasthana: Varanasi (India); Chaukhambha Orientalia: 2021 Chapter 21:verse 37. 163Available from: https://niimh.nic.in/ebooks/esushruta/?mod=read.
  • [9] India [Internet]. The drugs and cosmetics act, 1940 (act 23 of 1940) as amended by the Jan Vishwas (Amendment of Provisions) Act, 2023 (Act 18 of 2023): New Delhi (India); Ministry of Law and Justice, Government of India: 2023 Available from: https://pbspc.in/wp-content/uploads/2024/04/Amendments-of-Drugs-Cosmetics-Act.pdf.
  • [10] Sarngadhara [Internet]. Sarngadhara samhitha. Chowkhamba Sanskrit Series Office: Varanasi; 2021 Poorvakhanta, chapter 6. Verse 14-16. 61Available from: https://esamhita.wordpress.com/sharangdhara-samhita/.
  • [11] American Academy of Pediatrics Subcommittee on Hyperbilirubinemia. Management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation. Pediatrics 2004;114(1):297−316.ArticlePubMedPMCPDF
  • [12] Paul VK, Bagga A, editor. Ghai essential pediatrics. 10th ed. New Delhi (India): CBS Publishers & Distributors; 2023. 174.
  • [13] Kambli S, Khaire P, Kushwaha M. Ayurvedic, phytochemical and pharmacological information of Bhringraj (Eclipta alba): a review article. World J Pharm Res 2022;11(15):531−50.
  • [14] Jahan R, Al-Nahain A, Majumder S, Rahmatullah M. Ethnopharmacological Significance of Eclipta alba (L.) Hassk. (Asteraceae). Int Sch Res Not 2014;2014:385969. ArticlePubMedPMCPDF

Figure & Data

References

    Citations

    Citations to this article as recorded by  

      • PubReader PubReader
      • ePub LinkePub Link
      • Cite
        Download Citation
        Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

        Format:
        • RIS — For EndNote, ProCite, RefWorks, and most other reference management software
        • BibTeX — For JabRef, BibDesk, and other BibTeX-specific software
        Include:
        • Citation for the content below
        Efficacy of Bhringaraja Arka as an Add–On to Standard Care in the Management of Neonatal Jaundice – A Study Protocol for an Open Labelled Randomized Controlled Clinical Trial
        Perspect Integr Med. 2026;5(2):147-151.   Published online June 19, 2026
        Close
      • XML DownloadXML Download
      Figure
      • 0
      Efficacy of Bhringaraja Arka as an Add–On to Standard Care in the Management of Neonatal Jaundice – A Study Protocol for an Open Labelled Randomized Controlled Clinical Trial
      Image
      Graphical abstract
      Efficacy of Bhringaraja Arka as an Add–On to Standard Care in the Management of Neonatal Jaundice – A Study Protocol for an Open Labelled Randomized Controlled Clinical Trial
      No. Intervention Duration
      Group A Group B
      1 Bhringaraja Arka Nil 7 d or until remission
      2 Standard care
      Observation
      Phototherapy if needed
      Standard care
      A. Observation
      B. Phototherapy if needed
      7 d or until remission
      3 Post treatment
      Follow up
      Post treatment
      Follow up
      7 d after the treatment
      Table 1 Intervention and Treatment Protocol for Both Groups in Neonatal Jaundice

      N.B. (Total duration of study will be 14 days).


      Perspect Integr Med : Perspectives on Integrative Medicine
      TOP